| Data | Hora | Fonte | Título | Código | Companhia |
| 02/09/2009 | 07:00 | Edgar (US Regulatory) | Notice of Effectiveness (EFFECT) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 01/09/2009 | 10:05 | Edgar (US Regulatory) | Post-Effective Amendment to Registration Statement (POS AM) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 01/09/2009 | 09:00 | Business Wire | Allos Therapeutics to Hold Post Advisory Committee Conference Call | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 31/08/2009 | 10:31 | PR Newswire (US) | Seven Summits Research Releases Comments on Boeing, Joy Global, Ciena Corporation, TakeTwo Interactive and Allos Therapeutics | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 28/08/2009 | 14:27 | Dow Jones News | FDA Has Several Issues With Allos Data For Folotyn | NASDAQ:ALTH | Allos Therapeutics Inc. |
| 14/08/2009 | 17:16 | Edgar (US Regulatory) | Statement of Ownership (SC 13G) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 12/08/2009 | 19:01 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 10/08/2009 | 17:04 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 10/08/2009 | 11:25 | Business Wire | Allos Therapeutics Announces FDA Advisory Committee to Review Pralatrexate for the Treatment of Patients with Relapsed or Ref... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 04/08/2009 | 18:16 | Edgar (US Regulatory) | Quarterly Report (10-Q) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 04/08/2009 | 17:00 | Business Wire | Allos Therapeutics Reports Second Quarter 2009 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 23/07/2009 | 11:06 | Business Wire | Allos Therapeutics Launches Peripheral T-Cell Lymphoma Website | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 22/07/2009 | 09:00 | Business Wire | Allos Therapeutics to Report Second Quarter 2009 Results on August 4, 2009 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 20/07/2009 | 09:04 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (S-8) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 20/07/2009 | 09:00 | Edgar (US Regulatory) | Securities Registration Statement (simplified form) (S-3) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/07/2009 | 09:07 | Marketwired | BridgewaterEquity.com Free Fundamental Sector & Market Research on OCR, GGC, NWD, MPW, ALTH and NEXM | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/07/2009 | 09:00 | Business Wire | Allos Therapeutics Completes Enrollment in Randomized Phase 2b Trial of Pralatrexate in Patients with Advanced Non-Small Cell... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 29/06/2009 | 09:40 | PR Newswire (US) | InvestorSoup.com Researches Market Movers: Applied Materials, Allscripts-Misys, Allos, ValueVision, BGC Partners and Warren Reso | NASDAQ:ALTH | |
| 02/06/2009 | 07:05 | Edgar (US Regulatory) | Proxy Statement (definitive) (DEF 14A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 30/05/2009 | 09:00 | Business Wire | Allos Therapeutics Reports Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate at 45th ASCO Annual Meeting | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 26/05/2009 | 09:00 | Business Wire | Allos Therapeutics Announces FDA Accepts Pralatrexate NDA for Filing and Grants the Application Priority Review Status | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 14/05/2009 | 19:15 | Business Wire | Allos Therapeutics Announces Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate to be Presented at ASCO 2009 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 12/05/2009 | 09:00 | Business Wire | Allos Therapeutics to Present at the Eighth Annual JMP Securities Research Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/05/2009 | 17:00 | Business Wire | Allos Therapeutics Reports First Quarter 2009 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 30/04/2009 | 09:31 | Edgar (US Regulatory) | Amended Annual Report (10-K/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 28/04/2009 | 17:00 | Business Wire | Allos Therapeutics to Report First Quarter 2009 Results on May 5, 2009 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 19/04/2009 | 16:00 | Business Wire | Allos Therapeutics’ Pralatrexate Demonstrates Anticancer Activity in Multiple Cancer Cell Lines | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 15/04/2009 | 09:00 | Business Wire | Allos Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2009 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/04/2009 | 17:00 | Business Wire | Allos Therapeutics Announces Closing of Common Stock Offering | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/04/2009 | 17:10 | Edgar (US Regulatory) | Prospectus filed pursuant to Rule 424(b)(5) (424B5) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |